AssetMark Inc’s Esperion Therapeutics ESPR Stock Holding History

AssetMark Inc’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8	Closed	-$21	–	2147
2024 Q1	$21	Buy	+8	New	+$19	﹤0.01%	1880

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AssetMark Inc's ESPR Position: Q2 2024 in Review

AssetMark Inc sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 8 shares — an estimated $21 sold.

AssetMark Inc first reported a position in ESPR in Q1 2024 and held it in 1 quarter. The position peaked at $21 in Q1 2024. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

AssetMark Inc reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
AssetMark Inc sold 8 Esperion Therapeutics shares in Q2 2024, an estimated $21.
AssetMark Inc first reported a position in Esperion Therapeutics in Q1 2024 and held it in 1 quarter.
AssetMark Inc's Esperion Therapeutics position peaked at $21 in Q1 2024.
176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on AssetMark Inc's 13F filing for Q2 2024, filed 13 Aug 2024.